Apellis Pharmaceuticals CEO Cedric Francois Sells $6.35 Million in Stock

Apellis Pharmaceuticals CEO Cedric Francois sold 225,000 shares worth $6.35mln on August 29, 2025. The company achieved its third FDA approval in four years, expanding EMPAVELI's label and showing steady growth for SYFOVRE. However, challenges like high free goods utilization and co-pay assistance issues impacted revenue. Analysts have adjusted price targets for Apellis, reflecting both opportunities and challenges in its growth trajectory.

WALTHAM, Mass., July 2, 2025 — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has seen significant developments in its recent financial and operational landscape. On August 29, 2025, the company's CEO, Cedric Francois, sold 225,000 shares worth $6.35 million [3]. This move comes amidst a series of notable achievements and challenges for the biopharmaceutical company.

Apellis Pharmaceuticals has recently achieved its third FDA approval in four years, expanding the label for its EMPAVELI treatment. This approval has shown steady growth for SYFOVRE, the company's therapy for geographic atrophy secondary to age-related macular degeneration (GA) [1]. The company's focus on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs has been a driving force behind its recent success [2].

However, the company has faced challenges such as high free goods utilization and co-pay assistance issues, which have impacted its revenue. These issues have led analysts to adjust their price targets for Apellis, reflecting both opportunities and challenges in its growth trajectory [3].

In light of these developments, Apellis Pharmaceuticals management will participate in upcoming investor conferences, providing insights into the company's future prospects. The live conference webcasts will be available on the company's website, with replays available for approximately 30 days following the events [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/27/3139859/0/en/Apellis-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html
[2] https://finance.yahoo.com/quote/APLS/
[3] https://www.marketscreener.com/news/apellis-pharmaceuticals-insider-sold-shares-worth-6-352-743-according-to-a-recent-sec-filing-ce7c50dddc8df026